CXCR4 and ovarian cancer: In a mouse model of intraperitoneal ovarian cancer, compared with single drug therapy of AMD3100 (CXCR4 antagonist) and αPD-1, the antitumor efficacy of combined therapy in inhibiting tumor growth and prolonging the survival time of mice was significantly improved (35).